Nymox's Enlarged Prostate Drug Shows Great Promise
There are no Focus articles on RCDTF.
There are no Transcripts on RCDTF.
There are no News articles on RCDTF.
Mon, Feb. 10, 9:55 AM
- Apricus' (APRI) shares gain 8% after the company signs an exclusive licensing agreement with Italy's Recordati (RCDTF) to market Apricus' Vitaros cream for erectile dysfunction in Spain, Russia, Turkey, Ireland and other European countries, and in some African markets.
- Apricus will receive $3.8M up front, as much as $47M in sales milestone payments and royalties. (PR)
There are no StockTalks on this stock yet.
RCDTF vs. ETF Alternatives
Other News & PR